GeneHealth - Your precision medicine

Dilated Cardiomyopathy 1ee

Disease Details

Family Health Simplified

Buy Membership

Description: Dilated cardiomyopathy 1EE is a genetic disorder characterized by the enlargement and weakening of the heart's left ventricle, leading to impaired pumping ability and potential heart failure.
Type: Dilated cardiomyopathy 1EE (DCM1EE) is a type of dilated cardiomyopathy. The genetic transmission of DCM1EE is autosomal dominant.
Signs And Symptoms: **Dilated Cardiomyopathy (DCM):**

**Signs and Symptoms:**
- Shortness of breath (dyspnea), especially during exertion or when lying down
- Fatigue and general weakness
- Swelling (edema) in the legs, ankles, feet, abdomen, or veins in the neck
- Reduced ability to exercise
- Persistent cough or wheezing, possibly with frothy sputum
- Palpitations or irregular heartbeats
- Chest pain or discomfort
- Dizziness, lightheadedness, or fainting (syncope)

**NAN (Not Available or Not Applicable):**
- For some individuals, there may be no noticeable symptoms until the condition has progressed. Regular medical check-ups and diagnostic tests are crucial for early detection and management.
Prognosis: Dilated cardiomyopathy (DCM) is a condition where the heart's ability to pump blood is decreased due to an enlarged and weakened left ventricle. The prognosis for individuals with dilated cardiomyopathy type 1E (DCM 1E), caused by mutations in the LMNA gene, can vary widely based on factors such as the severity of the disease, response to treatment, presence of complications, and overall health of the patient.

In general, individuals with DCM 1E may experience progressive heart failure, arrhythmias, and an increased risk of sudden cardiac death. Regular follow-up with a cardiologist and adherence to prescribed treatments such as medications, lifestyle modifications, and potentially implantable devices or heart transplantation, are crucial for managing the condition and improving outcomes.
Onset: The onset of dilated cardiomyopathy (DCM) associated with the 1EE genetic marker can vary widely among individuals. It may present at any age, from childhood to late adulthood. The progression and severity can also differ significantly, making ongoing medical evaluation crucial for those at risk.
Prevalence: The prevalence of dilated cardiomyopathy (DCM) varies, but it is estimated to affect approximately 1 in 2,500 individuals in the general population. This condition can occur at any age but is most commonly diagnosed in middle-aged adults.
Epidemiology: Epidemiology for dilated cardiomyopathy (DCM), including subtypes like dilated cardiomyopathy 1EE, focuses on the prevalence, incidence, and demographic details:

1. **Prevalence and Incidence:**
- DCM affects approximately 1 in 250 to 1 in 400 individuals in the general population.
- Incidence rates vary by region and population but generally range from about 5 to 8 cases per 100,000 people annually.

2. **Demographics:**
- DCM can occur at any age but is most commonly diagnosed in middle-aged adults.
- It is slightly more prevalent in males than females.
- Familial cases account for approximately 20-50% of all DCM cases, depending on the population studied.

3. **Risk Factors:**
- Genetic predispositions, particularly mutations in genes like TTN, LMNA, MYH7, and others.
- Non-genetic factors include viral infections, alcohol abuse, and exposure to certain chemotherapy drugs.

4. **Geographical Variability:**
- The epidemiological patterns can vary globally, with some regions reporting higher incidences due to genetic or environmental influences.

If a specific subtype like dilated cardiomyopathy 1EE is in focus, it is important to note that it is one of the genetic variants of DCM and might have particular gene mutations associated with it. Detailed statistics specific to this subtype might be more limited in current literature.
Intractability: Dilated cardiomyopathy (DCM) is a condition where the heart's ability to pump blood is decreased due to an enlarged and weakened left ventricle. The intractability of DCM depends on various factors, including the underlying cause, the response to treatment, and the presence of any complications. While it can be managed with medications, lifestyle changes, and sometimes surgical interventions, certain cases may be more challenging to treat effectively, especially those that are genetically determined or associated with advanced heart failure. In such instances, the disease may be considered intractable, requiring advanced therapies such as ventricular assist devices or heart transplantation.
Disease Severity: Dilated cardiomyopathy 1EE is a subtype of dilated cardiomyopathy, a condition characterized by an enlarged and weakened heart muscle that impairs the heart's ability to pump blood efficiently. Disease severity can vary widely among individuals. Some may experience mild symptoms and remain stable for many years, while others may develop severe heart failure and require advanced treatments such as medication, implanted heart devices, or even a heart transplant. The course of the disease often depends on various factors, including the underlying cause, timely diagnosis, and management of the condition. "Nan" appears to be a placeholder or an error, as it doesn’t provide specific information related to disease severity.
Healthcare Professionals: Disease Ontology ID - DOID:0110453
Pathophysiology: Dilated cardiomyopathy (DCM) is a condition characterized by the dilation and impaired contraction of the left or both ventricles. The primary pathophysiological changes include:

1. **Ventricular Dilation**: The heart's ventricles become enlarged and the myocardial walls may become thinner, leading to a decrease in the heart's ability to pump blood effectively.

2. **Systolic Dysfunction**: Due to the dilation, the heart's ability to contract forcefully during systole is compromised, resulting in reduced ejection fraction.

3. **Neurohormonal Activation**: In response to decreased cardiac output, compensatory mechanisms such as activation of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system occur, which initially help but can eventually lead to further heart remodeling and worsening function.

4. **Cycle of Worsening Heart Function**: As the ventricles struggle to pump blood, fluid retention and increased cardiac workload perpetuate a cycle of worsening heart function, leading to heart failure symptoms.

The pathophysiology of DCM involves complex genetic, molecular, and structural changes contributing to these primary alterations in heart structure and function.
Carrier Status: Dilated cardiomyopathy 1EE (DCM1EE) is a condition characterized by the enlargement and weakening of the heart's ventricles, leading to impaired cardiac function. It can be inherited in an autosomal dominant manner. If a person is a carrier, they may have a 50% chance of passing the altered gene to their offspring. Carrier status typically refers to the presence of one altered copy of a gene associated with a disease. Diagnosis often involves genetic testing to confirm the presence of mutations in specific genes known to be associated with DCM1EE.
Mechanism: Dilated cardiomyopathy 1EE (DCM1EE) is a genetic form of dilated cardiomyopathy. The disease is characterized by the enlargement and weakening of the heart's ventricles, leading to impaired pumping ability.

**Mechanism:**
In DCM1EE, the heart muscle, particularly the ventricles, becomes dilated (enlarged) and cannot contract effectively. This reduces the heart's ability to pump blood efficiently, leading to heart failure and arrhythmias.

**Molecular Mechanisms:**
1. **Gene Mutation:** DCM1EE is primarily linked to mutations in the DES gene, which encodes the protein desmin. Desmin is a type of intermediate filament protein crucial for maintaining the structural integrity and function of cardiac muscle cells.

2. **Protein Dysfunction:** The mutations in the DES gene result in defective desmin proteins that fail to form proper intermediate filaments. This disrupts the cytoskeletal network within muscle cells, leading to weakened cellular architecture and impaired mechanical stability of the heart muscle.

3. **Cellular Disruption:** Defective desmin disrupts the normal alignment and function of myofibrils (the contractile units of muscle cells), affecting muscle contraction. Additionally, the impaired cellular integrity can lead to increased cellular stress and apoptosis (cell death).

4. **Impaired Signal Transduction:** Defective desmin filaments can also interfere with intracellular signaling pathways, calcium handling, and energy metabolism. These disruptions further compromise cardiac muscle function and contribute to the progressive nature of the disease.

Overall, the molecular mechanisms underlying DCM1EE revolve around the structural and functional impairments caused by mutations in the desmin protein, leading to compromised cardiac muscle performance and heart failure.
Treatment: Dilated cardiomyopathy 1EE (DCM1EE) is a genetic form of dilated cardiomyopathy. While specific treatments may vary based on individual patient conditions, general treatment approaches for dilated cardiomyopathy can include:

1. **Medications:**
- **ACE inhibitors** and **ARBs** to lower blood pressure and make it easier for the heart to pump blood.
- **Beta-blockers** to reduce heart rate and improve heart function.
- **Diuretics** to manage fluid retention and reduce the workload on the heart.
- **Aldosterone antagonists** to help manage heart failure symptoms.
- **Anticoagulants** to prevent blood clots.

2. **Lifestyle Changes:**
- Limitation of salt intake to manage blood pressure.
- Regular, moderate exercise as recommended by a healthcare professional.
- Avoidance of alcohol and recreational drugs.
- Monitoring weight and fluid intake.

3. **Device Therapy:**
- **Implantable cardioverter-defibrillators (ICDs)** to prevent sudden cardiac arrest.
- **Cardiac resynchronization therapy (CRT)** to improve the heart's efficiency.

4. **Surgical Options:**
- **Left ventricular assist devices (LVADs)** as a bridge to heart transplantation or as destination therapy.
- **Heart transplantation** for eligible patients with severe disease.

5. **Regular Monitoring and Follow-Up:**
- Periodic assessment by a cardiologist.
- Echocardiograms and other imaging studies to monitor heart function.
- Blood tests to track medication effects and overall health.

Management and treatment strategies should always be tailored to the individual patient and guided by a healthcare professional.
Compassionate Use Treatment: For dilated cardiomyopathy (DCM), including specific forms like DCM1EE, compassionate use treatments and off-label or experimental therapies may include:

1. **Gene Therapy**: Targeting underlying genetic mutations specific to DCM1EE.
2. **Cardiac Myosin Inhibitors**: Like mavacamten, primarily used for hypertrophic cardiomyopathy, but may have off-label potential.
3. **Mechanical Circulatory Support**: Experimental or early stage devices such as newer types of ventricular assist devices (VADs).
4. **Regenerative Medicine**: Stem cell therapy to promote cardiac regeneration.
5. **New Pharmacologic Agents**: Novel drugs undergoing clinical trials that target heart muscle function or fibrosis.

Consulting with a healthcare professional can provide the most relevant and up-to-date information on these options.
Lifestyle Recommendations: For dilated cardiomyopathy (DCM), lifestyle recommendations often include:

1. **Diet**: Adopt a heart-healthy diet that is low in sodium, saturated fats, and cholesterol. Emphasize fruits, vegetables, whole grains, and lean proteins.

2. **Exercise**: Engage in moderate, regular physical activity as advised by a healthcare provider. Avoid excessive or strenuous exercise, especially if symptoms are present.

3. **Alcohol and Smoking**: Avoid alcohol or consume in moderation as it can exacerbate heart problems. Completely avoid smoking.

4. **Weight Management**: Maintain a healthy weight to reduce the burden on the heart.

5. **Medication Compliance**: Take all prescribed medications as directed to manage symptoms and prevent complications.

6. **Regular Check-ups**: Have regular follow-ups with a healthcare provider to monitor the condition and adjust treatments as necessary.

7. **Stress Management**: Practice stress-reducing techniques such as meditation, yoga, or deep breathing exercises.

8. **Fluid Restriction**: In some cases, fluid intake may be limited to prevent fluid buildup.

Discuss these recommendations with a healthcare provider to tailor them to individual needs.
Medication: For dilated cardiomyopathy (DCM), treatment typically includes medications such as:

- ACE inhibitors (e.g., enalapril, lisinopril) to relax blood vessels and reduce the heart's workload.
- Beta-blockers (e.g., metoprolol, carvedilol) to slow the heart rate and reduce blood pressure.
- Diuretics (e.g., furosemide) to help remove excess fluid from the body.
- Anticoagulants (e.g., warfarin) to prevent blood clots if the patient is at risk.
- Aldosterone antagonists (e.g., spironolactone) to reduce fluid buildup and potential scarring of the heart muscle.

Please consult with a healthcare provider for personalized medical advice.
Repurposable Drugs: Dilated cardiomyopathy (DCM) leads to weakening of the heart muscle, which affects its ability to pump blood efficiently. Although there is no cure, several drugs approved for other conditions have potential for repurposing to manage DCM symptoms and progression. Some of these drugs include:

1. **Beta-blockers:** Typically used for hypertension and arrhythmias, they can help reduce heart rate and blood pressure, easing the workload on the heart (e.g., Carvedilol, Metoprolol).
2. **ACE inhibitors:** Used primarily for hypertension, they help relax blood vessels and reduce the workload on the heart (e.g., Enalapril, Lisinopril).
3. **Angiotensin II receptor blockers (ARBs):** Another class for hypertension, these also help relax blood vessels (e.g., Losartan, Valsartan).
4. **Aldosterone antagonists:** Used for heart failure and hypertension, these help remove excess sodium and reduce fluid buildup (e.g., Spironolactone, Eplerenone).
5. **Diuretics:** Commonly prescribed for hypertension and fluid retention, they help reduce the fluid load on the heart (e.g., Furosemide, Hydrochlorothiazide).
6. **Anti-arrhythmic drugs:** Used to manage irregular heartbeats (e.g., Amiodarone).

It's essential to consult a healthcare provider before taking any medication for DCM. They will consider individual health profiles and other conditions before prescribing a treatment regimen.
Metabolites: Dilated cardiomyopathy (DCM) is a condition where the heart becomes enlarged and cannot pump blood efficiently. The metabolic profile of DCM can vary, but some common metabolites associated with this condition include those involved in energy production, such as ATP, and those related to mitochondrial dysfunction and oxidative stress. Altered levels of metabolites such as lactate and fatty acids have also been noted, reflecting changes in energy metabolism and myocardial energy starvation. Elevated levels of certain amino acids and markers of inflammation may also be present.
Nutraceuticals: In the context of dilated cardiomyopathy (DCM), there's no well-established evidence supporting the use of specific nutraceuticals for treatment. Management primarily involves conventional medical therapies to improve heart function and symptoms. Consultation with a healthcare provider is essential for individualized advice.
Peptides: Dilated cardiomyopathy type 1E (DCM1E) is typically associated with mutations in the *LMNA* gene that encodes lamins A and C, which are structural components of the nuclear envelope. Peptides derived from these proteins may play a role in diagnostic or therapeutic strategies. However, clinical use of specific peptides for diagnosis or treatment is still under research. Nanotechnology (nan) is also being explored for potential applications in drug delivery systems and diagnostic tools to target affected myocardial cells more precisely. This field is evolving, and while promising, it remains primarily experimental.